DrugPatentWatch Database Preview

Validus Pharms Company Profile

« Back to Dashboard

What is the competitive landscape for VALIDUS PHARMS, and what generic alternatives to VALIDUS PHARMS drugs are available?

VALIDUS PHARMS has twenty-one approved drugs.

There is one US patent protecting VALIDUS PHARMS drugs.

There is one patent family member on VALIDUS PHARMS drugs in one country and ten supplementary protection certificates in six countries.

Summary for Validus Pharms

International Patents:	1
US Patents:	1
Tradenames:	19
Ingredients:	17
NDAs:	21

Drugs and US Patents for Validus Pharms

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Validus Pharms	CLAFORAN	cefotaxime sodium	INJECTABLE;INJECTION	050547-004	Dec 29, 1983		DISCN	Yes	No
Validus Pharms	LOTENSIN	benazepril hydrochloride	TABLET;ORAL	019851-003	Jun 25, 1991	AB	RX	Yes	No
Validus Pharms	BUMEX	bumetanide	TABLET;ORAL	018225-003	Jun 14, 1985	AB	RX	Yes	No
Validus Pharms	NORPRAMIN	desipramine hydrochloride	TABLET;ORAL	014399-007	Feb 11, 1982	AB	RX	Yes	No
Validus Pharms	TRENTAL	pentoxifylline	TABLET, EXTENDED RELEASE;ORAL	018631-001	Aug 30, 1984		DISCN	Yes	No

Expired US Patents for Validus Pharms

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Validus Pharms	ROCALTROL	calcitriol	CAPSULE;ORAL	018044-001	Approved Prior to Jan 1, 1982	3,697,559
Validus Pharms	NORPRAMIN	desipramine hydrochloride	TABLET;ORAL	014399-003	Approved Prior to Jan 1, 1982	3,454,698
Validus Pharms	ANZEMET	dolasetron mesylate	INJECTABLE;INJECTION	020624-001	Sep 11, 1997	4,906,775
Validus Pharms	BUMEX	bumetanide	TABLET;ORAL	018225-003	Jun 14, 1985	3,634,583
Validus Pharms	ROCALTROL	calcitriol	CAPSULE;ORAL	018044-002	Approved Prior to Jan 1, 1982	4,225,596

Paragraph IV (Patent) Challenges for VALIDUS PHARMS drugs

Drugname	Dosage	Strength	Tradename	Submissiondate
	Extended-release Capsules	100 mg		2014-05-23
	Extended-release Capsules	200 mg and 300 mg		2007-08-21

International Patents for Validus Pharms Drugs

Country	Patent Number	Estimated Expiration
Canada	2452588

Supplementary Protection Certificates for Validus Pharms Drugs

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
0565634	06C0030	France		PRODUCT NAME: EPROSARTAN MESYLATE; HYDROCHLOROTHIAZIDE; NAT. REGISTRATION NO/DATE: NL 32075 20060623; FIRST REGISTRATION: LI - 55783 01 20020607
0454511	99C0009	Belgium		PRODUCT NAME: IRBESARTAN / HYDROCHLOROTHIAZIDE; REGISTRATION NO/DATE: EU/1/98/086/001 19981015
0480717	98C0025	Belgium		PRODUCT NAME: LOSARTAN POTASSIUM; HYDROCHLOROTHIAZIDE; NAT. REGISTRATION NO/DATE: NL 20 037 19950215; FIRST REGISTRATION: FR - NL 20 037 19950215
0454511	SPC/GB99/008	United Kingdom		PRODUCT NAME: 2-N-BUTYL-4-SPIROCYCLOPENTANE-1-((2'-(TETRAZOL-5-YL)BIPHENYL-4-YL)METHYL)-2-IMIDAZOLIN-5-ONE)(GENERIC NAME IRBESARTAN) OPTIONALLY IN THE FORM OF ONE OF ITS SALTS AND HYDROCHLOROTHIAZIDE; REGISTERED: UK EU/1/98/086/001 19981015; UK EU/1/98/086/002 19981015; UK EU/1/98/086/003 19981015; UK EU/1/98/086/004 19981015; UK EU/1/98/086/005 19981015; UK EU/1/98/086/006 19981015
0266730	SPC/GB97/005	United Kingdom		PRODUCT NAME: DOLASETRON, OR A PHARMACEUTICALLY-ACCEPTABLE ACID ADDITION OR QUATERNARY AMMONIUM SALT THEREOF; REGISTERED: UK 04425/0150 19960926

Similar Applicant Names

Applicants may be listed under multiple names.
Here is a list of applicants with similar names.

• Validus Pharms
• Validus Pharms Inc